John P. Sharp - 24 Feb 2022 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc

Role
Chief Financial Officer
Signature
/s/ John P. Sharp
Issuer symbol
N/A
Transactions as of
24 Feb 2022
Net transactions value
$0
Form type
4
Filing time
28 Feb 2022, 18:30:49 UTC
Previous filing
23 Nov 2021
Next filing
24 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHASQ Restricted Stock Unit Award $0 +24,750 $0.000000 24,750 24 Feb 2022 Common Stock 24,750 Direct F1, F2
transaction PHASQ Employee Stock Option (right to buy) Award $0 +115,500 $0.000000 115,500 24 Feb 2022 Common Stock 115,500 $1.13 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit is the economic equivalent of one share of PhaseBio Pharmaceuticals, Inc. common stock and is converted into common stock upon vesting subject to the reporting person's continued service through each such date.
F2 These Restricted Stock Units vest in equal one-third amounts on April 1, 2023, 2024, and 2025.
F3 The shares subject to the option shall vest in equal monthly installments over 48 months from February 24, 2022, subject to the reporting person's continued service through each such date.